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https://doi.org/10.1002/nbm.4019VERDICT (vascular, extracellular and restricted diffusion for cytometry in tumours)
estimates and maps microstructural features of cancerous tissue non‐invasively using
diffusion MRI. The main purpose of this study is to address the high computational
time of microstructural model fitting for prostate diagnosis, while retaining utility in
terms of tumour conspicuity and repeatability.
In this work, we adapt the accelerated microstructure imaging via convex optimization
(AMICO) framework to linearize the estimation of VERDICT parameters for the pros-
tate gland. We compare the original non‐linear fitting of VERDICT with the linear
fitting, quantifying accuracy with synthetic data, and computational time and relia-
bility (performance and precision) in eight patients. We also assess the repeatability
(scan‐rescan) of the parameters.
Comparison of the original VERDICT fitting versus VERDICT‐AMICO showed that
the linearized fitting (1) is more accurate in simulation for a signal‐to‐noise ratio
of 20 dB; (2) reduces the processing time by three orders of magnitude, from 6.55 sec-
onds/voxel to 1.78 milliseconds/voxel; (3) estimates parameters more precisely; (4)
produces similar parametric maps and (5) produces similar estimated parameters with
a high Pearson correlation between implementations, r2 > 0.7. The VERDICT‐AMICO
estimates also show high levels of repeatability. Finally, we demonstrate that
VERDICT‐AMICO can estimate an extra diffusivity parameter without losing tumour
conspicuity and retains the fitting advantages.
VERDICT‐AMICO provides microstructural maps for prostate cancer characterization
in seconds.
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2 of 15 BONET‐CARNE ET AL.1 | INTRODUCTIONProstate cancer (PCa) is the most frequently diagnosed cancer among men in high‐income countries and the secondmost frequently diagnosed cancer
inmenworldwide.1 Currently, digital rectal examination, serumprostate specific antigen (PSA)—a non‐specific blood test—and trans‐rectal ultrasound‐
guided biopsy are the primary diagnostic tools.2 Histological analysis remains the main test for PCa diagnosis and grading, and is the standard
procedure used to guide treatment. To obtain histological information a portion of tissue is taken from the prostate and observed under a microscope
to detect changes in the tissue architecture (biopsy). However, biopsy is invasive and painful, and can result in complications for the patient. Non‐
invasive alternatives are highly sought after, as they offer several major benefits: (i) they are safer for the patient; (ii) they do not disrupt tissue, enabling
serial examinations andmonitoring; (iii) they can examine extended areas of an organ, as opposed to biopsy samples, which are spatially limited. Multi‐
parametric prostate MRI is a non‐invasive diagnostic tool, which has been shown to potentially reduce unnecessary primary biopsies in 27% of the
patients. However, current non‐invasive imaging techniques lack the sensitivity and specificity required for non‐invasive cancer grading.
Diffusion‐weighted MRI (DW‐MRI) is becoming increasingly important in the assessment of malignant tumours. At the 2008 National Cancer
Institute sponsored open consensus conference, experts reached consensus on the use of DW‐MRI as a cancer imaging biomarker.3,4 However,
current usage of DW‐MRI does not fully exploit its potential. Most cancer DW‐MRI studies use the apparent diffusion coefficient (ADC) for
tumour assessment.5-8 ADC reflects the mobility of water molecules within tissue, which provides useful contrast in cancerous tumours, where
ADC values are generally observed to be lower than healthy tissue. However, the ADC values in PCa and benign tissue overlap substantially, con-
founding the overall specificity.9,10 ADC is a gross measurement that conflates various physiological parameters, including cell size, shape,
permeability, subcellular architecture and vascular perfusion effects.11 The dependence of ADC on a variety of histological features simultaneously
can mask significant alterations in tissue architecture indicative of malignancy. Moreover, ADC lacks biological specificity and fails to associate
contrast changes with particular microstructural effects.10
Advanced model‐based imaging techniques can overcome some of the limitations of simplistic diffusion‐based indices, such as ADC, by
estimating distinct parameters reflecting separate influences on the signal. In particular, in cancer imaging, VERDICT (vascular, extracellular and
restricted diffusion for cytometry in tumours)12,13 is a three compartment model‐based DW‐MRI technique that is designed to capture the main
microstructural properties of cancerous tissue. VERDICT has shown promising results in preclinical studies for characterizing microstructural tissue
properties of xenograft tumour models.12 In a clinical setting for PCa, VERDICT has demonstrated the ability to discriminate normal and malignant
prostate tissue13 and to characterize specific Gleason grades.14 However, as with many model‐based techniques,15-17 VERDICT requires a computa-
tionally expensive non‐linear fitting procedure to estimate the model parameters. This prevents immediate inspection of VERDICT parameter maps,
which is possible with ADC mapping. Non‐linear fitting is also vulnerable to local minima, which can cause convergence to a sub‐optimal solution,
adding to the noise and uncertainty in derived parameter maps. Another limitation of the original VERDICT implementation is that it requires certain
parameter constraints for stability, such as fixing the intra‐ and extra‐cellular diffusivities, despite evidence that such parameters may vary.18,19
Recently, ultrafast‐fitting algorithms have been developed to address the high computational cost of model‐based microstructure‐imaging tech-
niques.20-22 Graphical processing units (GPUs) provide a brute‐force solution, using a parallelized approach, to reduce the computational time as in
References 20 and 22. Although some overhead lies in GPU‐based design and implementation, once adapted for GPU platforms the fitting time
can be reduced by several orders of magnitude compared with standard central processing units, and is limited only by the number of cores on the
GPU. Alternatively, through linearization and convex optimization, the accelerated microstructure imaging via convex optimization (AMICO) frame-
work21 addresses the cost limitation for each individual fitting operation and is therefore complementary to speed‐ups obtained fromGPU computing.
AMICO is guaranteed to find the global minimum, albeit of a reformulated objective function, providing more reliable and stable parameter maps.
Hence, AMICO potentially affords relaxation of overly restricted constraints, such as fixed diffusivity parameters, that were constrained to stabilize
non‐linear fitting. Both solutions have dramatically reduced the computational time of microstructure‐imaging techniques in the brain, e.g. ActiveAx,
NODDI and CHARMED.15,16,23Whilst GPUs do not reduce the computational cost, only the computational time, AMICO actually reduces the cost via
the linearization. AMICO could be implemented in GPUs and further accelerate the fitting. Rapid‐fitting algorithms are important to analyse the large
volume of data arising from studies and clinical trials and, potentially, to improve patient workflow during the clinical process. For example, the UK
Biobank imaging project24 requires fitting up to 100 000 imaging datasets; only through the use of ultrafast‐fitting algorithmsNODDI parameters have
been included as imaging phenotypes in the project.25,26 Cohorts in PCa studies are also increasingly large27-29 and thus necessitate similar techniques.
The AMICO framework can be adapted to linearize the estimation of the VERDICT parameters (VERDICT‐AMICO), allowing a fast‐fitting
approach.30 Here, we present VERDICT‐AMICO and demonstrate its benefits over the original VERDICT implementation. We utilize AMICO to
fit the VERDICT model for prostate tissue13 to demonstrate reduction in computation time and robust parameter estimation. We explore the
reliability of VERDICT‐AMICO using simulated and clinical data. We test whether we can retain the qualitative conspicuity for cancer lesions in
parametric maps, and we evaluate the repeatability of the technique within a test–retest experiment. Finally, we use AMICO to demonstrate
the possibility of unfixing previously fixed VERDICT parameters.2 | THEORY
We first review the original VERDICT model for prostate using non‐linear fitting, and the general AMICO framework.21 Then, we describe
VERDICT‐AMICO.
BONET‐CARNE ET AL. 3 of 152.1 | VERDICT for prostate
The VERDICT framework characterizes water diffusion in vascular (VASC), extracellular‐extravascular (EES) and intracellular (IC) compartments in
tumours.12 Mathematically, VERDICT is the sum of three parametric models that describe the DW‐MRI signal in each separate water population
assuming zero exchange between them. The normalized diffusion signal for the VERDICT model is
S ¼ ∑3i¼1fiSi (1)
where f i is the proportion of signal with no diffusion weighting (b = 0) from water molecules in population i (IC, EES or VASC), 0 ≤ f i ≤ 1,
∑3i¼1fi ¼ 1. The model has three different volume fraction parameters: f IC, f EES and f VASC.
For prostate,13 the diffusion signal for the IC compartment (S1) is modelled with impermeable spheres and has dIC (IC diffusivity) and R
(cell radius) as parameters. The sphere (terminology from Reference 17) models particles diffusing inside impermeable spherical boundaries with
non‐zero R using the Gaussian phase approximation.31 In our implementation, as in the previous works that used the sphere model,12,13,17 the
numerical approximation of the implementation used is 100 roots.
The model for the EES compartment assumes a diffusion tensor (DT) model, in particular an isotropic DT with diffusivity dEES as parameter.
The normalized DT signal is
S2 ¼ exp −bdEESGTIG
 
(2)
where I is the identity tensor, G is the gradient direction and b = (Δ − δ/3)(γδ|G|)2 is the b‐value for the pulse gradient spin echo (PGSE) sequence, Δ
is the time between the onsets of the two pulses, δ is the pulse gradient duration and γ is the gyromagnetic ratio.
The vascular compartment uses the “astrosticks” model (terminology from Reference 17) for isotropically distributed zero‐diameter restricting
cylinders or “sticks”, and has pseudo‐diffusivity P as the only parameter. The signal is given by
S3 ¼ ∫Srp nð Þdn; R ¼ 0; Sr ¼ exp −bP n⋅G2
  
(3)
where n is the stick direction with uniform distribution p, p(n) = (4π)−1.
The model has three independent unknown parameters: f IC, R and f EES. f VASC is calculated as f VASC = 1 − f IC − f EES, and the diffusion and
pseudo‐diffusion coefficients are fixed, as in Reference 13, to dIC = dEES = 2 × 10
−9 m2/s, P = 8 × 10−9 m2/s.
2.2 | AMICO
AMICO is a framework that reformulates microstructural imaging techniques as linear systems of equations enabling use of convex optimization
techniques (https://github.com/daducci/AMICO/).21 More concretely, AMICO uses a dictionary of potential parameter combinations,
Φ ¼ ϕij
 
∈ RNd×Nkþ , and convex optimization to find the weight vectorbx ∈ RNkþ for the dictionary elements that best matches the vector containing
the Nd measurements y ∈ R
Ndþ . Hence, the system can be formulated as a convex optimization problem as follows:
bx ¼ argmin
x ≥ 0
1
2
Φx−yk k22 þ λΨ xð Þ (4)
where ‖·‖2 is the standard ℓ2‐norm in R
n, the positivity constraint is explicitly imposed as the coefficients x correspond to volume fractions, Ψ(·)
represents a generic regularization function32 and the parameter λ > 0 controls the trade‐off between data and regularization terms. The AMICO
dictionary can also be partitioned into different sub‐matrices to correspond to different compartments considered in the model of choice. We will
use this property to adapt AMICO for the three compartments of the VERDICT model. A pre‐defined dictionary for the fitting instead of continuous
variables as possible solutions is required to linearize the problem with a fast‐computational performance. Nevertheless, the number of solutions is
not limited, as the final parameter estimates are a linear combination of each dictionary value according to the real‐valued weight vector bx.
2.3 | VERDICT‐AMICO
We adapt the AMICO framework for prostate VERDICT to estimate the three independent unknown parameters as in Reference 13: f IC, R and f EES.
The dictionary for VERDICT‐AMICOΦ ¼ ϕij
 
∈ RNd×Nkþ is partitioned into three sub‐matrices, corresponding to the VERDICT compartments:
Φ ¼ ΦrjΦejΦv  (5)
where Φr ∈ RNd×Nr , Φe ∈ RNd×Ne and Φv ∈ RNd×Nv each model the IC, EES and vascular contributions of the diffusion signal in the voxel with
Nk = Nr + Ne + Nv. The regularization function used is the basic Tikhonov regularization with the same λ value (λ = 0.001) as used in Reference 30.
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follows.
• Each column inΦr ∈ RNd×Nr corresponds to the signal attenuation of the water molecules restricted within spheres17 with a specific radius. We
considered Nr = 17 radii values linearly spaced from 0.01 μm to 15.1 μm. The corresponding signal profiles are estimated according to the
“sphere”, assuming an IC diffusion coefficient dIC = 2 × 10
−9 m2/s.
• A single compartment,Φe ∈ RNd×Ne where Ne = 1, describes the EES with the same fixed value for the diffusion coefficient dEES = 2 × 10−9 m2/
s. The signal model is free isotropic diffusion.
• A single compartment,Φv ∈ RNd×Nv where Nv ¼ 1; is considered to account for the vascular volume fraction. Signal is estimated according to
the “astrosticks” model and pseudo‐diffusivity is fixed, P = 8 × 10−9 m2/s.13
The estimated coefficients bx are partitioned into bxrjbxejbxv , and the VERDICT‐AMICO estimated parameters are obtained as
fIC ¼ ∑Nrj¼1bxrj (6)
R ¼ ∑
Nr
j¼1R
′
jbxrj
∑Nrj¼1bxrj (7)
fEES ¼ bxe and fVASC ¼ bxv, where j ∈ {1,…,Nr} indexes the cell radius R′j corresponding to the jth atom in Φr. The original VERDICT only assumes one
R per voxel. When there is more than one R per voxel, original VERDICT estimates the average. By averaging the distribution of radii, the two
methods are equivalent.
VERDICT‐AMICO inherits parameter constraints from the original non‐linear implementation of the model. The enhanced robustness of the
AMICO fitting may be able to avoid these constraints. We hypothesize that VERDICT‐AMICO can estimate a diffusivity parameter without
compromising the overall parameter estimation. We previously tested different AMICO dictionaries and observed that different dIC values have
a small impact on the other parameter estimates with fixed perfusion.30 Thus, we unfixed dEES and kept dIC and P fixed with their original values,
dIC = 2 × 10
−9m2/s and P= 8 × 10−9m2/s.133 | METHODS
We first provide details of the patient population, data acquisition and image processing, region of interest (ROI) selection, and synthetic data. We
then describe the experiments comparing the two implementations. Finally, we demonstrate the possibility of estimating an additional previously
fixed VERDICT parameter.
3.1 | Patient population
This study has been performed with local ethics committee approval as part as of the INNOVATE clinical trial.33 Between April and July 2016,
eight men were prospectively recruited and provided informed written consent. The inclusion criteria were the following: (1) suspected PCa or
(2) undergoing active surveillance for known PCa. Exclusion criteria were the following: (1) previous hormonal, radiation therapy or surgical treat-
ment for PCa and (2) biopsy within 6 months prior to the scan. Patient characteristics are shown in Table 1.
3.2 | Data acquisition and pre‐processing
All patients underwent a standard European Society of Uroradiologists compliant mp‐MRI,2 on a 3 T scanner (Achieva, Philips Healthcare, Best,
Netherlands) supplemented by VERDICT DW‐MRI. VERDICT DW‐MRI was acquired with PGSE and an optimized imaging protocol for VERDICT
prostate adapted from Reference 34 with five b‐values of 90–3000 s/mm2 in three orthogonal directions using a pelvic coil. Table 2 shows the
combinations of Δ, δ,|G|, TE (echo time) and TR (repetition time) for each b‐value. For b < 100 s/mm2 the number of averages (NAV) = 4 and for
b > 100 s/mm2 NAV = 6 with voxel size 1.3 × 1.3 × 5 mm and matrix size 176 × 176. For each b‐value (specific TE‐TR combination) a separate
b = 0 image was acquired to correct for T1 and T2 dependence. The scan time for the VERDICT DW‐MRI protocol is 12 min. Three patients
(1‐3) were re‐scanned with the VERDICT DW‐MRI sequence without a time interval between the scans.
To reduce possible artefacts caused by patient movement during scanning, VERDICT DW‐MRI data was registered using a rigid registra-
tion.35,36 The transformation matrix was computed using the b = 0 images, and then was applied to the b = 0 and the subsequent DW‐MRI.
We normalize the data using the b = 0 images, hence for each voxel the number of normalized measurements is Nd= 20 (five b‐values with three
directions each, and five b = 0 images for each TE). The AMICO dictionary size is limited by the VERDICT DW‐MRI acquisition; we cannot have
more dictionary terms than measurements Nd as we are using the simple form of regularization.
TABLE 2 Optimized imaging protocol for VERDICT prostate characterization
b‐values [s/mm] Δ [ms] δ [ms] |G| [mT/m] TE [ms] TR [ms]
90 23.8 3.9 61.2 50 2482
500 31.3 11.4 44.3 65 2482
1500 43.8 23.9 32 90 2482
2000 34.3 14.4 67.7 71 3945
3000 38.8 18.9 60.0 80 3349
Δ, gradient separation time; δ, gradient duration;|G|, gradient strength; TE, echo time; TR, repetition time.
TABLE 1 ROI characteristics
Patient
ID
Patient
age [y]
PSA
[ng/mL]
ROI
ID
Slice
(No/14)
No of voxels
(Acquisition 2)
Likert
(No/5)
Prostate
zone
Gleason score
(if known) Biopsy type
ROI
group ID
1 63 10.2 1 9 26 (8) 3 PZ benign targeted 25/09/2016 1
2 9 59 (55) 4 PZ 3 + 4 2
3 9 28 (25) 2 TZ N/A 3
4 11 71 (89) 4 TZ benign 4
2 66 4.7 5 8 10 (10) 2 PZ N/A targeted 18/07/2016 5
6 7 16 (17) 4 PZ 3 + 3 6
7 7 25 (26) 2 TZ N/A 3
8 7 42 (39) 4 TZ 3 + 4 7
3 67 4.86 13 5–6 109 (108) 5 PZ 3 + 4 targeted 31/06/2017 2
14 8 26 (25) 3 PZ 3 + 3 6
15 8 28 (26) 2 TZ N/A 3
16 8 60 (66) 4 TZ 3 + 3 8
4 73 10.20 9 8 48 2 PZ benign targeted 06/10/2016 1
10 6 29 5 PZ 3 + 4 2
11 7 16 4 PZ 3 + 4 2
12 7 27 2 TZ benign 4
5 49 6.7 17 7 25 2 PZ benign TRUS 27/05/2010 1
18 7 26 2 TZ benign 4
6 57 4.04 19 8 25 2 PZ N/A targeted 04/11/2016. 5
20 6 29 2 TZ N/A 3
21 6 37 4 TZ 3 + 3 8
22 8 125 2 CZ N/A 9
7 52 11.1 23 7 26 3 PZ benign prostatectomy 02/11/2016 1
24 6–7 133 5 PZ 4 + 3 10
25 8 26 2 TZ 3 + 4 7
8 64 6.03 26 11 35 2 PZ benign targeted 30/09/2016 1
27 8 10 4 PZ benign 1
28 9 33 2 TZ benign 4
TRUS, transrectal ultrasound.
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A board‐certified radiologist (EJ) evaluated parametric maps from VERDICT‐AMICO voxelwise fitting (Figure 1A), using Osirix Version 8.0 (Pixmeo,
Bernex, Switzerland). The radiologist manually placed ROIs on the VERDICT‐AMICO maps, guided by the conventional mp‐MRI. mp‐MRI findings
were reported by an experienced uroradiologist (SP, 11 years of prostate mp‐MRI reporting experience). If biopsy‐confirmed tumours were pres-
ent, the largest lesion in each zone was manually contoured (transition zone, TZ, peripheral zone, PZ, or central zone, CZ) following the tumour
shape. In normal tissue, the ROIs were standard 40 mm2 circles. Normal tissue ROIs were drawn in the TZ and the PZ (Likert 2 on mp‐MRI).
The Likert score is a five‐point scoring system used for the interpretation of mp‐MRI for PCa.37 Clinical biopsy information was also used to con-
firm where to place the ROIs (Figure 1A).
We grouped the 28 different ROIs according to Gleason score and prostate zone, as we expect them to have similar underlying microstruc-
tures. When the Gleason score was unknown we grouped the ROIs according to the Likert score. This procedure resulted in 10 grouped ROIs (g‐
ROIs) (Figure 1B). Table 1 provides details for the ROIs and g‐ROIs. We compute the signal‐to‐noise ratio (SNR) in the VERDICT data using the
method of Dikaios et al.,38 which gives a mean SNR of 19.97 (range 10.56 to 40.38).
3.4 | Synthetic data
We generate synthetic data with 30 different values for f IC, f EES and R (equally spaced from 0.02 μm to 15 μm) creating all the possible parameter
combinations that satisfy 0 ≤ f IC + f EES ≤ 1. We only set values of R for f IC > 0. The generated signal accounts for Rician noise,
39 with b = 0 SNR
FIGURE 1 ROI generation and grouping selection. A, Steps followed to generate the individual ROIs. B, Criteria used to group the different ROIs
and generate the g‐ROIs
6 of 15 BONET‐CARNE ET AL.set to 20, 50, ∞. We include 10 different noise instances for each SNR (20 and 50), which are sufficient to guarantee reproducible estimates. The
error of our estimated signal plateaus after five instances for SNR = 20 and two instances for SNR = 50. Thus, for each instance of noise we had a
total of 13 050 voxels.
To generate the synthetic data and for the original fitting implementation we used the open‐source Camino toolkit.40 Camino uses an iterative
optimization procedure with the Levenberg–Marquardt algorithm that mitigates the problem of local minima and Rician noise, as in References 13
and 17. All experiments were conducted on a 3.1 GHz Intel Core i7, 8 GB RAM DDR3.
3.5 | Fitting performance experiments
We test the VERDICT model using both the original non‐linear fitting and the linear VERDICT‐AMICO. We use synthetic data to compare both
implementations for accuracy against ground‐truth estimates. Then, to test the fitting performance with clinical data, we compare the variance of
the estimated parameters in different known tissue types. We analyse ROIs within the same g‐ROIs together. We then contrast the parametric
maps in terms of run‐time and fitting performance.
Two board‐certified radiologists (SP and EJ) examined the VERDICT‐AMICO parametric maps for qualitative tumour conspicuity (contrast
between tumour and surrounding tissue) to ensure tumour enhancement and clinical relevance. Then, we compared the chi‐squared objective function
maps ( f obj), which are sum of square differences adjusted to account for offset Gaussian noise, to evaluate the robustness of the fitting, as in Reference
17. Finally, we test the repeatability of both procedures in three patients (scan‐rescan) using Bland–Altman agreement analysis.41 We emphasize that
the different parameter maps for both VERDICT and VERDICT‐AMICO should be viewed side by side to aid in their interpretation. For example, the
estimated R value is less relevant if the f IC is almost zero in that region, and in areas where f obj is high all estimated parameters are less reliable.
3.6 | dEES estimation with VERDICT‐AMICO experiment
Here, we use both fitting methods (original non‐linear and VERDICT‐AMICO) to estimate the extra parameter (dEES) in two datasets, and we
examine the run‐time and goodness of fit. The VERDICT‐AMICO dictionary with unfixed dEES is
• Nr = 13 different radii (linearly spaced from 0.01 μm to 15.1 μm) with fixed dIC = 2 × 10
−9 m2/s.
• Ne = 5 diffusion coefficients for EES: dEES = 1.1 × 10
−9, 1.6 × 10−9, 2.1 × 10−9, 2.6 × 10−9 and 3.1 × 10−9 m2/s.
• Nv = 1, P = 8 × 10
−9 m2/s.
Details about the rationale and the discretization of dEES can be found in Reference 30.4 | RESULTS
4.1 | Synthetic data
Figure 2 shows the performance of both fitting methods, VERDICT and VERDICT‐AMICO, using synthetic data as a function of SNR. Figure 2A
shows the absolute errors for each estimated parameter. We compute the mean absolute errors for the overall combination of the input
FIGURE 2 Quantitative evaluation using synthetic data. Performance comparison of the two fitting implementations of VERDICT as a function
of SNR for the synthetic data. A, Mean absolute error obtained with both models with respect to the ground‐truth. Bars are the standard
deviations of the errors. B, Absolute errors for each estimated parameter as a function of original synthetic values. f IC, intracellular volume
fraction; f EES, extracellular‐extravascular volume fraction; R, radius [μm]; f VASC, vascular volume fraction
BONET‐CARNE ET AL. 7 of 15parameters. The mean error reduces as SNR increases for both procedures. However, this reduction is less obvious for VERDICT‐AMICO, mainly
because it performs poorly at infinite SNR. Nevertheless, at a typical noise level for clinical acquisitions (SNR = 20), VERDICT‐AMICO generally
exhibits a lower absolute error than VERDICT (p < 0.001 for the objective function in the absolute error comparison). VERDICT‐AMICO performs
worse for f IC, but the overall fitting, as revealed by the objective function errors, is better. VERDICT‐AMICO maintains estimated fitting precision
comparable to VERDICT when the SNR is reduced. The reductions in the fitting precision estimates measured by the ratio between the standard
deviation at SNR = 20 and SNR = ∞ for f IC, f EES, f VASC and R are 1.75, 1.00, 1.08 and 0.95 for VERDICT‐AMICO, and 2.39, 3.84, 4.82 and 0.87
for VERDICT.
Figure 2B presents the mean absolute errors for each estimated parameter as a function of the ground‐truth synthetic values to highlight the
dependence of fitting errors. The estimated parameters f IC and R at SNR = 20 and SNR = 50 show approximately constant error scores across the
ground‐truth values for both fitting procedures. For f IC, the AMICO fitting procedure makes slightly larger errors than the original fitting. In con-
trast, the VERDICT‐AMICO error in f EES increases with the real f EES value, and the original fitting for VERDICT is worse when f EES < 0.75 at
SNR = 20 or 0.17 < f EES < 0.58 at SNR = 50.
4.2 | Clinical data
We also evaluate the performance of both methods using clinical data. First, we compare the computational times for parametric maps (Table 3).
The VERDICT‐AMICO formulation reduces the processing time by more than three orders of magnitude, from 6.55 s/voxel to 1.78 ms/voxel. To
TABLE 3 Time required to compute each prostate ROI with non‐linear (VERDICT) and linear (VERDICT‐AMICO) fitting procedures
Patient ID
Slice
(No/14)
Original
VERDICT [h] VERDICT‐AMICO [s]
No of
voxels
VERDICT/
voxel [s]
VERDICT‐AMICO/
voxel [ms]
1 acq 1 9 2.319 2.824 1240 0.644 2.278
11 2.200 1.8052 1118 7.087 1.615
1 acq 2 9 2.392 2.33 1220 7.060 1.915
11 2.120 1.787 1098 6.952 1.628
2 acq 1 8 1.86 1.652 1038 6.456 1.592
7 1.889 1.752 1064 6.393 1.647
2 acq 2 8 1.823 1.745 1038 6.323 1.682
7 1.926 1.963 1064 6.517 1.845
3 acq 1 5–6 3.182 2.254 1692 6.771 1.332
8 2.097 2.236 1062 7.109 2.106
3 acq 2 5–6 3.079 2.148 1609 6.889 1.335
8 2.150 1.989 1086 7.130 1.832
4 8 1.748 1.788 840 7.493 2.129
6 1.610 1.835 809 7.165 2.269
7 1.931 1.694 956 7.275 1.772
5 7 1.998 1.708 1105 6.512 1.546
6 8 1.751 1.700 987 6.388 1.723
6 1.653 1.446 951 6.259 1.521
7 7 0.994 1.175 528 6.783 2.227
6–7 1.910 1.546 1021 6.737 1.515
8 1.232 1.307 605 7.333 2.161
8 11 1.892 1.529 1028 6.629 1.488
8 1.211 1.213 652 6.689 1.861
9 1.412 1.343 773 6.578 1.738
Mean 6.548 s/voxel 1.781 ms/voxel
8 of 15 BONET‐CARNE ET AL.explore the acceleration provided by AMICO, independent of the programming language used, we calculated the processing time for VERDICT
(Camino) using a full MATLAB pipeline (instead of Java) in 600 voxels. The mean processing time for VERDICT using the MATLAB pipeline is
0.75 s/voxel, still two orders of magnitude slower than VERDICT‐AMICO.
We then compare parameter estimates for all voxels within ROIs. Figure 3 illustrates the parameter estimates for all voxels within four g‐ROIs
with a confirmed tissue type (normal and Gleason Score 3 + 4 in TZ and PZ). VERDICT‐AMICO shows similar estimates to VERDICT for f IC and
f EES, with Pearson correlations r
2 (sum of squared error) of 0.91 (0.049) and 0.74 (0.079), respectively. The VERDICT‐AMICO estimates for f IC and
R in tumour lesions are statistically significantly higher, and f EES values are lower compared with VERDICT, but both methods produce physiolog-
ically plausible values within the same range. The precisions of the fit estimates (σ) are better for the AMICO implementation, being 0.15, 0.16,
0.20 and 0.33 × 10−5 for f IC, f EES, f VASC and R respectively, compared with 0.15, 0.24, 0.24 and 0.41 × 10
−5 for the original implementation.
Individual ROI analysis yields similar results (not shown).
Figure 4 presents a qualitative comparison of parametric maps for two patients with a standard ADC image from the mp‐MRI (A), the
corresponding ROIs for that slice superimposed onto a T2 reference image (B) and VERDICT (C) and VERDICT‐AMICO (D) maps. The two
board‐certified radiologists agreed that tumour conspicuities are similar for the two fitting methods and reveal similar qualitative differences
between tumour and normal tissue. For example, in both cases f IC is higher and f EES is lower in tumour compared with normal tissue, as seen
in References 13 and 42. In general, the two implementations present similar behaviours. Maps obtained using AMICO appear less noisy than
those with the original non‐linear fitting. This effect is more evident for the radius map.
Figure 5 presents correlations of the estimated parameters from the repeatability experiment for 12 ROIs with both methods. Overall, most
parameters are repeatable with high correlation coefficients. The AMICO implementation has the highest correlation coefficients (except for
f VASC). For both methods, R appears the least repeatable. We further test the repeatability of R by recalculating correlation coefficients whilst
excluding ROIs with fewer than 10 voxels (ROI 1 from Table 1), and voxels where f IC was too small to produce a reliable signal ( f IC < 0.001).
The repeatability does not improve considerably for VERDICT‐AMICO (r2 = 0.037, SSE = 1.5 × 10−6) or for the non‐linear fitting (r2 = 0.034,
SSE = 2.1 × 10−6). However, the reproducibility coefficient (RPC) and the coefficient of variation (CV) from the Bland–Altman test are better
for VERDICT‐AMICO (RPC = 29%, CV = 15%) than for VERDICT (RPC = 53%, CV = 27%).4.3 | dEES estimation with VERDICT‐AMICO
Table 4 shows the computational time for both fitting implementations after unfixing dEES. In both cases, the extra parameter requires more com-
putational time, 2.20 ms/voxel and 7.68 s/voxel for the linear and the non‐linear fitting respectively. Figure 6 demonstrates a visual comparison of
FIGURE 3 Quantitative comparison of
VERDICT maps versus VERDICT‐AMICO.
Parameter estimates for all voxels within the
ROIs of four different g‐ROIs (1, 2, 4 and 7)
for all the estimation procedures (VERDICT
and VERDICT‐AMICO). f IC, intracellular
volume fraction; f EES, extracellular‐
extravascular volume fraction; R, radius [μm];
f VASC, vascular volume fraction. GS, Gleason
score. Arbitrary units. *p < 0.01; ** p < 0.001
BONET‐CARNE ET AL. 9 of 15the maps for both fittings. Note the additional maps: the dEES map, and an example of a parametric combination ( f IC/dEES) that exhibits increased
tumour conspicuity. Maps reveal reduced dEES and f EES in lesions while retaining a high f IC. We also observe that f VASC is lower than with the
original model. VERDICT‐AMICO with the new dictionary achieves lower objective function values than with fixed dEES.5 | DISCUSSION
In this study, we adapted the AMICO framework for the VERDICT technique for PCa characterization to reduce the computational cost of the
original fitting. We tested VERDICT‐AMICO against the non‐linear fitting procedure in terms of (a) accuracy against ground‐truth simulation
values, (b) computational time, (c) fitting precision in different tissue types, (d) qualitative tumour conspicuity and (e) repeatability. Finally, we
demonstrated the estimation of an extra VERDICT parameter: the EES diffusivity (dEES). The principal benefit of the AMICO framework in prostate
is that it provides an acceleration factor of several orders of magnitude compared with non‐linear fitting, whilst offering robust parameter estima-
tion, and without significantly affecting the parameter maps.
First, we tested the accuracy of both fitting procedures using synthetic data with an extensive range of parameter values within biophysical
limits (Figure 2). We also checked the accuracy at different SNR levels. For finite SNR, VERDICT‐AMICO appears to produce errors that vary less,
as a function of parameter values, than the original VERDICT. For infinite SNR, VERDICT‐AMICO performance is worse than that of VERDICT;
this is an artefact of the regularization term—regularization parameters fail when dealing with perfect data because numerical calculations may
cause instabilities and yield an unsatisfactory solution.43 However, with an SNR of 20, similar to the level in our clinical samples, VERDICT‐AMICO
is more accurate than VERDICT for most parameters. In the future, to improve the fitting procedure, we could adjust the regularization term ad
hoc by estimating the SNR for each region. However, this solution requires a prostate segmentation as input, since the SNR is different in different
image regions. The noise model may also influence our results, as AMICO assumes Gaussian noise. Many papers suggest that when the SNR is
high enough the noise can be approximated as Gaussian.39 For SNR = 20, AMICO with Gaussian noise has acceptable results; however, future
versions of AMICO will incorporate non‐Gaussian noise.
Second, we examined the computational run‐time for the two fitting procedures. Results in Table 3 illustrate that AMICO provides an
acceleration factor of several orders of magnitude compared with the non‐linear fitting, while the parameter estimation remains similar to the
original VERDICT fitting. This speed‐up makes it practical for researchers to analyse entire volumes, rather than single slices, of prostate data using
standard computers. AMICO thus allows the computation of parametric maps without human intervention for precise gland/lesion segmentation.
Additionally, AMICO would allow VERDICT to be computed directly during the scan, similar to the current use of ADC in clinics. Analysing the
whole prostate enables the observation of multiple lesions from large datasets, facilitating translation of the method to routine clinical use.
FIGURE 4 Qualitative comparison of VERDICT maps for two different patients: VERDICT versus VERDICT‐AMICO. A, Standard ADC image. B,
Corresponding ROIs on a T2 image: the whole prostate (light green) and ROIs 1 and 7 (green), 3 and 6 (orange) and 2 and 8 (red). ROI description
shown in Table 1. C, D, Parametric maps for VERDICT and VERDICT‐AMICO, respectively. ROIs are overdrawn on the f IC map for illustrative
purposes. The white square highlights a region with greater homogeneity in the objective function for VERDICT‐AMICO compared with
VERDICT. f IC, intracellular volume fraction; f EES, extracellular‐extravascular volume fraction; R, radius [μm]; f VASC, vascular volume fraction. a.u.,
arbitrary units
10 of 15 BONET‐CARNE ET AL.VERDICT‐AMICO can fit the whole volume of interest (30 976 voxels) in less than 1 minute. Improvement in computation time could also poten-
tially be achieved using large GPUs.20,22 However, AMICO provides an entirely complementary and direct reduction in computational cost.
We measured the parameter precision in various prostate regions in benign and cancerous tissue (Figure 3). We observed differences in f IC
among normal PZ and TZ, with higher f IC for normal TZ. This could potentially be due to the fact that TZ is the main site of origin of prostatic
hyperplasia, which is also characterized by a higher volume of epithelial cells, much like tumours.44 Like VERDICT, VERDICT‐AMICO tends to
overestimate vascular fraction; we see higher f VASC in the presented results than we would expect from histology.
44 This could be a similar effect
to the overestimation of cerebrospinal fluid volume fraction in white matter with NODDI that also arises as a result of fixing diffusivity
parameters.45 We no longer observe vasculature overestimation after unfixing the EES diffusivity.
Visual comparison (Figure 4) by board‐certified radiologists showed that the two methods produce similar parametric maps. VERDICT‐AMICO
retains the qualitative conspicuity in lesions and revealed the same trends observed in Figure 3. Overall, the VERDICT‐AMICO formulation produces
smoother and more robust maps suitable for radiological inspection, as it enables location of the global minimum more reliably than the original
fitting. Greater homogeneity in the minimum objective function maps support this assertion (see the highlighted white square in Figure 4).
We further tested the clinical applicability of VERDICT‐AMICO by investigating the repeatability of the parameter estimates (Figure 5).
Results showed high levels of repeatability for most parameters for both methods. However, the AMICO implementation improves repeatability
over the non‐linear fitting for f IC and f EES. For R, the repeatability is low for both methods. Future work will investigate this result using histology.
FIGURE 5 Repeatability. Correlation plots for parameter estimation comparison between two different acquisitions for the 12 repeated ROIs
(ROIs 1 to 12) for VERDICT (A) and VERDICT‐AMICO (B). Median values for all voxels within each ROI were used. f IC, intracellular volume
fraction; f EES, extracellular‐extravascular volume fraction; R, radius [μm]; f VASC, vascular volume fraction; r
2, Pearson's R‐value squared; SSE, sum
of squared error; SD, standard deviation
TABLE 4 Time required to compute each prostate ROI after unfixing dEES for two different patients with non‐linear (VERDICT) and linear
(VERDICT‐AMICO) fitting procedures
Patient ID Slice (No/14)
Free dEES
VERDICT [h]
Free dEES
VERDICT‐AMICO [s]
No of
voxels
Free dEES VERDICT/
voxel [s]
Free dEES VERDICT‐AMICO/
voxel [ms]
1 acq 1 9 2.72 3.23 1240 7.90 2.60
11 2.49 2.50 1118 8.03 2.23
1 acq 2 9 2.68 2.68 1220 7.91 2.20
11 2.44 2.26 1098 8.02 2.06
2 acq 1 8 2.13 2.16 1038 7.39 2.08
7 2.15 2.30 1064 7.30 2.17
2 acq 2 8 2.16 2.19 1038 7.49 2.11
7 2.18 2.22 1064 7.38 2.09
Mean 7.68 s/voxel 2.19ms/voxel
BONET‐CARNE ET AL. 11 of 15In our dataset, parameter estimation in tumour regions was less repeatable than in normal tissue (results not shown). This is probably because
tumour tissue can be highly heterogeneous, especially when compared with normal tissue, so small errors in the ROI definition can produce
greater differences. A more extensive dataset with many tumour types is needed to further test parameter repeatability in cancer lesions.
Next, we examined whether the VERDICT‐AMICO improvement in computational time was retained when estimating an additional VERDICT
parameter, the diffusivity dEES.
30 We also estimated dEES with the original non‐linear fitting (Figure 6). As expected, the parametric maps presented
similar results for both methods. VERDICT‐AMICO exhibits the same improvement over the original fitting for computational time and robustness
after unfixing dEES. For both fittings, the parameter estimates with the new dictionary are more biophysically plausible and in closer agreement
FIGURE 6 Qualitative comparison of VERDICT maps after unfixing dEES for two different patients: VERDICT versus VERDICT‐AMICO. A,
Standard ADC image. B, Corresponding ROIs on a T2 image: the whole prostate (light green) and ROIs 1 and 7 (green), 3 and 6 (orange) and 2
and 8 (red). ROI description shown inTable 1. C, D, Parametric maps for VERDICT and VERDICT‐AMICO after unfixing dEES, respectively. ROIs are
overdrawn on the f IC map for illustrative purposes. f IC, intracellular volume fraction; f EES, extracellular‐extravascular volume fraction; R, radius
[μm]; f VASC, vascular volume fraction; dEES, extracellular‐extravascular diffusivity [m
2/s]. a.u., arbitrary units
12 of 15 BONET‐CARNE ET AL.with histology44 than the original VERDICT estimates (fixed dEES). This is especially evident for the vascular volume fraction f VASC. This is an
important improvement, as the general lower estimation of vasculature is in line with histological analysis of our samples (not shown), showing
a vascular component of approximately 1%. Unfixing dEES could allow our model to account better for the lumen space as a separate component
from stroma; tissue previously captured as part of the vascular compartment might be now part of the EES compartment. A very small vascular
component could explain the noisier f VASC estimates compared with the rest of the parameters. However, we note that our samples lack highly
vascularized cancer lesions. Currently, the literature relating vascularization and aggressive cancers is controversial for prostate.46-50 However,
there is general agreement that increased angiogenesis is an important factor in determining tumour development and prognosis.51 Aggressive
cancers need to be quickly identified and they do show significant vasculature; therefore, it is important to capture the vasculature component
of the tissue, which justifies the inclusion of a vascular component in our model.
BONET‐CARNE ET AL. 13 of 15In Figure 6 we compare VERDICT‐AMICO and VERDICT with an extra unfixed parameter, dEES. As in the original VERDICT‐AMICO imple-
mentation with fixed dEES, the rest of the estimated parameters ( f IC, R, f EES) do not generally hit the upper boundary constraint compared with
the original VERDICT implementation. In Figure 6, R hits the upper boundary in some voxels for VERDICT also after unfixing dEES, which evidences
that AMICO improves and stabilizes the fitting. Despite the more realistic estimates after unfixing dEES, both VERDICT and VERDICT‐AMICO lose
some tumour conspicuity in the f IC maps compared with the original model, which is a clinically important aspect. However, the contrast remains
among the full set of maps. For example, we show that the conspicuity can be recovered and perhaps enhanced using the f IC/dEES combination.
One possible explanation for the enhanced conspicuity could be a decreased inter‐cell space and increased tortuosity, which is consistent with a
higher partial volume of epithelial cells and loss of lumen space.11 VERDICT with fixed dEES may still have clinical utility for highlighting tumours. In
the future, we will run a comprehensive study involving clinicians to further compare the potential clinical use of the two implementations.
The main limitation of the AMICO framework is that the fitting results depend to some extent on the dictionary values, as the regularization
has to be set empirically.21 For this reason, we used histological information to guide the selection of dictionary values. Biopsy results confirm that
the estimated maps provide plausible values even with the limited dictionary. However, more samples from larger datasets are required to validate
the VERDICT parameters with histology, and this is beyond the scope of this study. Future efforts with larger cohorts will focus on clinical VER-
DICT parameter validation, using methods such as those of Reference 52 to further investigate VERDICT as a non‐invasive MRI‐based cancer bio-
marker. VERDICT‐AMICO also inherits the limitations and assumptions of the VERDICT prostate model, which need to be taken into
consideration when interpreting the parameter estimates. For example, the current model does not account for permeability between the different
components or for large differences in T2 within the same voxel (T2 heterogeneity),
53 which could cause bias in the parameter estimation. In the
future, we will study the T2 and permeability effects and incorporate the findings into the VERDICT model. Nevertheless, the results from this
study and previous work provide good evidence that VERDICT‐AMICO can provide useful information, improving current methods.
To conclude, VERDICT‐AMICO's fast and robust fitting highlights important microstructural differences between tumours and normal pros-
tate tissue in seconds, which is crucial for utilizing VERDICT as a diagnostic tool. Longer‐term, fast‐fitting algorithms such as AMICO will be essen-
tial for the translation of promising techniques like VERDICT to widespread clinical applications. Our results suggest that VERDICT‐AMICO maps
provide additional value over the original VERDICT prostate implementation, and we hope they will be a valuable source of clinical imaging bio-
markers. However, further studies are required to validate this assumption. The VERDICT‐AMICO implementation will be freely available online
(http://mig.cs.ucl.ac.uk Resources tab). VERDICT‐AMICO shows promise as a MRI‐based tool for PCa grading and detection, which could be used
to enhance the diagnostic potential of current prostate mp‐MRI.
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